It is well established that direct oral anticoagulants (DOACs) are the cornerstone of
anticoagulant strategy in atrial fibrillation (AF) and venous thromboembolism (VTE) and …

Background There is an increasing amount of literature on direct oral anticoagulant (DOAC)
laboratory monitoring. The aims of the present review were to evaluate published data on …

A universal anti‐Xa assay for the determination of rivaroxaban, apixaban and edoxaban
drug concentrations would simplify laboratory procedures and facilitate widespread …

Despite evolving evidence, the use of direct oral anticoagulants (DOACs) in patients with
extremes of body weight remains controversial. This study aimed to measure the impact of …

Background: Oral anti-Xa inhibitors have demonstrated noninferiority to vitamin K
antagonists (VKAs) for the prevention of stroke in patients with atrial fibrillation and recurrent …

The role of drug-level monitoring among patients using direct-acting oral anticoagulant
(DOAC) is unclear. We aimed to investigate its 'real-life'utilization and effect on clinical …

Objective Rivaroxaban is a specific factor Xa (FXa) inhibitor for venous thromboembolism
treatment. Recently, increasing evidence have reported the beneficial effects of rivaroxaban …

Introduction A reversal agent for factor Xa (FXa) inhibitors, andexanet alfa, was Food and
Drug Administration approved without extensive study of clinical effectiveness, due to an …

Andexanet alfa is approved for the reversal of factor Xa inhibitors in patients with major
bleeding events. We aimed to review the incidence of effective hemostasis with andexanet …

Background Applying a single anti-Xa assay, calibrated to unfractionated heparin to
measure rivaroxaban, apixaban, and edoxaban would simplify laboratory procedures and …